Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies

Published on 17 Jul 2023
Last Updated on 01 Sep 2023

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received two or more prior therapies. The decision was based on the unfavourable cost-effectiveness of T-DXd at the price proposed by the company compared with chemotherapy. 

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies (Published 1 Sep 23) [PDF, 132 KB]

PES Trastuzumab deruxtecan for previously treated HER2-positive advanced gastric cancer (Updated 1 Sep 23) [PDF, 126 KB]